About PaxMedica

PaxMedica is a clinical-stage biopharmaceutical company tackling one of the
world’s most challenging conditions – Autism Spectrum Disorder (ASD). ASD affects
approximately 1% of the world’s population, and there are no approved treatments for the core
symptoms, involving social interaction, repetitive behavior and speech and non-verbal
communication. ASD is a condition that affects the lives of millions of children and adults, their
families and caregivers, and we hope to make a difference.